Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Insiders have been given themselves shares for a long time. What we have been saying about this setup is those “investors “ in the offering are not locked up. They buy at 4 sell at 7-8. The selling pressure will sink the pps how far I don’t know but as student pointed out the whole idea of the offering is to raise a few bucks to get the drug to trial and uplist.
Why do you think the pps will not collapse post RS? I’m looking for anything positive
And you know it? Or you just speculating?
I don't know how people are acting surprised by the S1. The terms are fairly standard and ultimately much better for shareholders than convertible notes in the OTC world. Insiders have a 6 month lock-up and will have every incentive to see the company appreciate in value. Additionally, the lack of warrants should increase the likelihood that any institution partaking in the offering holds their shares opposed to selling them and riding the warrants for free for upside. The stock will trade very thinly and be volatile. This is and always has been a high-risk investment with large upside and the risk of significant losses. That all being said, if we complete the uplist, the chances of reaching the large upside should increase meaningfully.
All of us the common shareholders going to be screwed after uplist Anyway, it will take another 3 to 5 years and maybe something will be achieved by this company. No one is able to sell anything unless they sell it for 0.005. oh well
Animal studies are obviously only to prove safety and, as far as I know only humans develop AMD. Clearly if CUBT is moving forward and planning human trials then the animal trials must have shown the safety in animals.
Remember that Metformin has been prescribed as a first line treatment for type 2 diabetes since 1995. CUBT is using Metformin in a topical eye solution.
Student, what were the final results on the animal test? Was the results better than expected? In your opinion, have you talked to any big money about investing after the uplist?
It says right in the S-1 that getting the drug to the point of a trial will cost over a million dollars (earlier versions had $2M). The NIH is paying the bulk of the first clinical trial, but they have to get the drug to that point.
Remember that NIH through the CRADA will be paying MOST of the IND costs for the AMD trial (all except travel expenses). CUBT has to pay to provide the drug, but NIH will pay for the trial.
CUBT needs to raise enough money to qualify to be uplisted to the NYSE/Amex.
You won’t get the S-1 cancelled, and without it the company will have to take on convertible notes, or do the RS anyway and sell stock, or be dead. They have no cash, have a $2M debt hanging over their heads, and have made zero progress since the first offering/RS/uplist failed. That first S-1 wreaked of a company looking to pile up some cash to pay themselves for a few years, and this latest version only commits to spending $2M of the $7M raised on the drug (with $2M paying debt and the rest uncommitted).
How do we get the S1 cancelled?? I think stockholders could contact the sec?
This is way worse the alleged crypto crap Gary gessler is fighting
Thoughts? He does represent the little guys
Steve, listen to these guys and respond. How does their version NOT play out?
All current commons shareholders will be obliterated here once RS is done...all small bio do it, rinse and repeat for cash to progress...no institutional investors will touch this
Successful AMD program will not be enough alone. A partnership or licensing deal will be necessary to prevent further dilution.
Well that’s all speculation. If the pps is 8 post split and sellers emerge who bought at 4. And the stock price collapse to under a 1 no institutions will buy for the same exact reason
Scam
Yep. That’s the whole point of the data assembled in the sticky, even though it is dated. A couple of those companies are trading way lower right now.
I admit I didn’t read it usually board members help each other out and support each other clear you behave differently let’s agree I will never engage with you again and you won’t with me. Deal?
Hahah betting hundreds of thousands on a scam. Complete looser
The common retail investors that initially believed here and took this to over .20 gets crushed and institutional investors are more important to the CEO.
Yippers.
It looks like it's going to be going down from 0.02 to 0.01 after the offering so it looks like it's going to be diluted really bad and it's going to be gone from $4 probably to $0.20 which is not really good. A a lot of dilution .not good for common shareholders.
We are all screwed
The S1 (when approved by the SEC), is a filing that registers and makes all new shares offered by Spartan Capital in the offering free trading shares. The funding will allow for the uplisting and open the door for institutional investors (who can not buy penny unlisted stocks) to invest in CUBT.
The stock price will be driven in the future by the progress of the AMD program.
And did you find out anything in S1? How long the lockup for new investors is?
What is the lock up period. Since insiders aren’t putting up $$$ I don’t think it matters. What matter is lock up for the new investors who are getting a 50% discount on the shares they acquire at $4
There is a lock-up period for insiders.
Correct. What is the RS ratio please
Obviously you didn't read the S1 if you don't know what the reverse split is.
Is there a lock up period? What is the rs ratio 10000 to 1?
Why raise just 5-6 million like why not go for higher pps? And raise 20mil?
This looks like a fairly standard deal when uplisting. They need to raise funds to move the company forward. While the $4 price for the offering is a little lower than I hoped, it dies have the advantage of not including warrants with each unit which is fairly atypical based on similar deals I've looked at. Hopefully without free warrants, those who take part in the funding will be more inclined to hold long term. Time will tell.
Suspicious. I’m speculating some negative results behind the scenes from another study or something… that will hinder advancing their initiative… or why else dilute and create zero shareholder wealth.
And they'd want their shares registered because?
It's so they can sell them. With the RS and offering, they're selling stock at less than half the PPS it is today and diluting it by over 50%. Read the sticky and tell me if it's a smart move for someone to maintain their holdings through all that.
Whew, lucky for you , you sold all your shares
No, but I’m sure they’ll be another”quiet period” were they’re not allowed to release any news for another two years like last time lol
Have you read the S1? Clearly a massive effort went into this and it must have cost a huge amount of money for all the legal reviews. Wouldn’t a scam look for an easier approach?
Selling Stockholders listed in S1 merely REGISTERS their shares for sale, doesn't determine when/if they sell. It's the note holders and series B shareholders.
Yep, selling stock for $4 post RS...
That's $0.01 today.
And there's some "selling stockholders" also getting their stock registered to sell.
It is S1 Day! Happy S1 Day one and all.
Happy S1 Day!! Or is that in 2 more weeks?
You bet your farm on this?
Yeah who holding a lot of shares is screwed. 0.02 reverse split 1 to $400 $8 selling to the investors for $6 and it's going to go 0.015 or 6 after reverse split. It's going to take 5 years to recover if it will ever happen.
Bankruptcy looming for some including me
22% drop wow this companies going places
Oh, the share of printing scheme that is CUBT sad what does management has done to investors just a bunch of scammers
Garbage management
So when is the uplist this year or next?
Who the f*** knows was going to happen. We are all tired of waiting for the last 3 years
Followers
|
295
|
Posters
|
|
Posts (Today)
|
5
|
Posts (Total)
|
44434
|
Created
|
03/17/09
|
Type
|
Free
|
Moderators Eagle1 Student of the Game trader59 |
OTC: CUBT http://CurativeBiotech.com INVESTOR PRESENTATION https://curativebiotech.com/news-and-media/presentations Curative Biotechnology, a development-stage biomedical company, focuses on novel treatments for rare diseases. The company focuses on therapies with potentially accelerated development paths as a result of the disease, the nature of the therapeutic itself, or the stage of clinical development. Its pipeline candidates include CURB906, an antibody-drug conjugate for targeting CD56 positive brain tumors; and IMT504, a novel immune therapy to treat rabies. The company has an agreement with Mid-Atlantic BioTherapeutics, Inc. to develop an adjuvant for the COVID-19 vaccines which enhance antibody response. Current Drug Pipeline https://curativebiotech.com/pipelineTreatments for six (6) Ocular conditions, one (1) Oncology, one (1) Infectious disease and one (1) vaccine adjunct candidate* Metformin eyedrops for treatment of Acute Macular Degeneration (AMD) AMD is a visually threatening condition, most often found in patients over age 60. Early and Intermediate AMD are characterized by enlarged drusen behind the eye’s retina. Close to 10% of the world’s population is over 60, increasing the prevalence of age-related macular degeneration. Dry AMD accounts for 80-90% of AMD cases, while wet AMD is 10-20% of cases. Currently there are no approved drug treatments for Dry AMD or Geographic Atrophy (late stage dry AMD). Wet AMD is caused by blood vessels that leak in the retina. These abnormal blood vessels may leak fluids or blood into the back of the eye. Curative Biotech will reformulate metformin to treat intermediate dry AMD and Geographic Atrophy for the first indications. Development to be led by the lead inventor on the NEI Patents, Dr. Kapil Bharti. Curative is in negotiations with NEI to conduct the first clinical trial. This product may be eligible for 505(b)(2) treatment as a reformulation of an already approved drug. The global age-related macular degeneration (AMD) market is expected to attain a value of $8.9 billion by 2022 Stargardt DiseaseStargardt disease is a type of inherited age-related macular degeneration that causes vision loss in children or young adults.The retina contains light-sensing cells called photoreceptors, which include rods and cones. Rods are in the outer retina and help people when lighting is dim and dark. Cones are in the macula and help people see intricate visual detail and color. Both cones and rods negatively affected in Stargardt disease, cones are more strongly impacted in people who have Stargardt disease. The Global Stargardt Disease Therapeutics Market is estimated to be valued at US$ 213.5 million in 2023 and is expected to exhibit a CAGR of 31.7% during the forecast period (2023 - 2028). Retinitis PigmentosaRetinitis pigmentosa (RP) is a genetic disorder which leads to a gradual loss of sight, causing a deterioration of night vision and peripheral vision. People with RP experience a gradual decline in their vision, because photoreceptors degenerate. Retinitis pigmentosa, is a condition where patients typically loses ability to see at night in young years, side vision in middle age, and focal vision in later in his/her life due to relentless loss of cone photoreceptor cells. Retinitis Pigmentosa (RP), an acquired retinal condition that causes retinal depletion, is an uncommon illness. Its underlying manifestations are decreased night vision along with loss of fringe vision. It slowly causes visual impairment. There is no conclusive remedy for retinitis pigmentosa. Hence medical institutions and various research and development centers are researching to develop a full proof cure for this disease which is boosting the growth of global retinitis pigmentosa market. ChoroideremiaChoroideremia is a hereditary degeneration of the retina in males that causes a gradual loss of vision. It starts in early childhood with night-blindness, then follows with peripheral vision loss and eventually progresses to the loss of central vision. The lack of a functional protein in the retina causes cell death that is followed by the gradual deterioration of the retinal pigment epithelium, photoreceptors, and the choroid. Choroideremia results in progressive loss of vision and is more prominent in males. The first symptom of choroideremia is usually night blindness that occurs at an early stage. Global Choroideremia Treatment market is expected to account for $4.3 Billion by 2028 Late Onset Retinal DegenerationLate-onset retinal degeneration occurs in adulthood and is an inherited retinal dystrophy. It leads to central vision loss. https://www.sciencedaily.com/releases/2021/12/211209133927.htm Diabetic RetinopathyDiabetic retinopathy is the leading cause of blindness in adults. It is a complication of diabetes that causes damage to the blood vessels of the retina. At first, diabetic retinopathy may cause no symptoms or only mild vision problems. Eventually, it can cause blindness. The global diabetic retinopathy market reached a value of US$ 7.64 Billion in 2020. and is expected to register a CAGR of 7.6% over the forecast period. Market growth can be primarily attributed to increased funding by regulatory bodies for researching ocular disorders. REFERENCE LINK: https://curativebiotech.com/pipeline |
From 1990 to 2017, worked at National Cancer Insitute of the NIH. Since 2017 Director of Center for Antibody Therapeutics at University of Pittsburgh. Dr. Dimitrov’s major long-term goal is the development of clinically useful therapeutics and vaccines based on human monoclonal antibodies in different formats including engineered antibody domains, chimeric antigen receptors, bispecific antibodies and antibody drug conjugates. He has authored or coauthored more than 370 articles, several books, and is the inventor or coinventor of more than 100 inventions, patent applications or patents. Dr. Dimitrov is the lead inventor on the Antibody Drug Conjugate patent exclusively licensed to Curative Biotech from the National Cancer Institute to treat glioblastoma.
Currently President of Sohn Health Strategies and Adjunct Professor at the University of California, San Francisco.
Dr. Sohn has deep biopharmaceutical industry knowledge with over thirty (30) years of U.S. and global experience with expertise in the development and introduction of new medicines for patients and diseases with significant unmet needs. Her skill sets include strategic product development, business development and the introduction of new vaccines, pharmaceutical products and consumer healthcare brands.
Dr. Sohn started the U.S. Vaccine Business for SmithKline Beecham and led the launch of its first vaccine in the U.S. and helped shape their global vaccine portfolio pipeline as a member of the International Vaccine Steering Committee. Subsequently, she led the US commercialization of the company’s largest CNS product. Dr. Sohn later became senior vice president, Worldwide Business Development and a member of the global executive committee at GlaxoSmithKline Consumer Healthcare where she led U.S. and global transactions, including the $1.3 billion acquisition and integration of Block Drug and the $566 million acquisition of CNS, Inc.
Boca Raton, FL, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Curative Biotechnology Inc. (OTC: CUBT) ("Curative Biotech" or the "Company"), a development-stage biomedical company focused on novel treatments for rare diseases and conditions, announced today that it has successfully completed its Investigational New Drug (IND) enabling Tolerance and Toxicology Study of Metformin HCL Solution by Topical Instillation (eye drops) in Rabbits.
Paul Michaels, Chairman and President of Curative Biotechnology, said, "We are pleased to announce the successful completion of these important studies, outlined in our Pre IND meeting with the FDA. We are now able to move on to preparing the Company's first IND application to move our Metformin reformulation into a clinical trial to treat Intermediate Dry Age-Related Macular Degeneration (AMD) and Geographical Atrophy (GA) resulting from AMD."
Michaels continued, "Both Dry AMD and GA are currently unmet medical needs with no FDA approved efficacious treatment options. As previously announced, we will be conducting the first in human study under a CRADA (Cooperative Research and Development Agreement) with the National Eye Institute of the National Institutes of Health, in Bethesda Maryland."
About Macular Degeneration (AMD)
Macular Degeneration is a common eye disorder among people over 50 causing blurred or reduced central vision due from the deterioration of the inner layers of the macula. The macula is the part of the retina that gives the eye clear vision in the direct line of sight. Dry AMD accounts for 80-90% of all age-related macular degeneration (AMD cases), while wet AMD represents 10-20% of patient cases. Currently there are no approved drug treatments for Dry AMD or Geographic Atrophy (late-stage dry AMD).
About Curative Biotechnology, Inc. http://curativebiotech.com
Curative Biotechnology, Inc. (Curative Biotech) is a development stage biomedical company focused on novel therapies for rare diseases. The Company is focused on identifying, acquiring and developing disease modifying therapeutic drug candidates with a concentration on rare disease indications. Curative Biotech has ongoing programs in three different therapeutic areas: infectious disease, neuro oncology and degenerative eye disease. The Company's pipeline includes IMT504, CURB906 and Metformin Reformulation. IMT504 is a novel immune therapy to treat rabies and an adjuvant for vaccines. CURB906 is a fully humanized CD56 monoclonal antibody carrying a cytotoxic drug conjugate directly to the tumor cancer site to kill the tumor by inhibiting tumor growth and migration of the tumor. Metformin Reformulation is targeting the treatment of intermediate and late-stage Age-Related Macular Degeneration (AMD) disease.
Contact:
Steve Chizzikhttps://www.wsj.com/articles/curative-biotechnology-announces-completion-of-ind-enabling-reformulated-metformin-hcl-eye-drop-study-01672923305
Connectyx (now Curative Botechnology) Announces Grant of Exclusive Worldwide License from National Institutes of Health for Repurposing Metformin to Treat Degenerative Eye Disease
Boca Raton, FL, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Connectyx Technologies Holdings Group, Inc. (OTC: CTYX) (“Connectyx” or the “Company”), a development-stage biomedical company focusing on novel treatments for rare diseases today announced it has entered into an Exclusive Patent License Agreement to practice inventions contained within the patent applications listed below with the National Eye Institute (NEI), of the National Institutes of Health (NIH), including the repurposed use of Metformin to treat Retinal Degeneration (RD).
The license patent rights include U.S. provisional patent application No. 62/899,899 and entitled, “Druggable Targets to Treat Retinal Degeneration” filed September 13, 2019 (E-227-2017-US-01); International Patent Application No.: PCT/US2020/050540 and entitled, “Druggable Targets to Treat Retinal Degeneration” filed September 11, 2020 (E-227-2017-PCT-O2); and U.S. and foreign patent applications claiming priority to the applications. The territory for the exclusive license is worldwide.
The degeneration of the Retinal Pigment Epithelium (RPE) is associated with various types of RD such as Stargardt disease, retinitis pigmentosa, choroideremia, late-onset retinal degeneration (L-ORD), and age-related macular degeneration (AMD). In the United States, 11 million people are affected by some form of AMD.
Research has shown that Metformin, an FDA-approved drug that has been widely used for the treatment of diabetes in the United States since 1995, can activate AMP-activated protein kinase, can reduce vascular endothelial growth factor (VEGF) secretion, and can correct baseline calcium levels in patient RPE cells. The new treatment indications will require reformulating the drug into an eye drop, injectable or other topical delivery method to be able to deliver sufficient drug to the RPE layer to have a therapeutic effect. This reformulated drug should be eligible for a 505(b)(2) accelerated development path. While the field of use covers treating any degenerative eye disease, the Company is targeting Stargardt, a currently untreatable orphan disease that causes vision loss in children, as the first indication for this therapeutic product.
Paul Michaels, Chairman and President of Connectyx, said, “We are pleased to expand our product portfolio with the addition of reformulated and repurposed Metformin, which is the fifth most prescribed drug in the United States. This very promising product adds a second in licensed product from the NIH to our development portfolio. As stated above, we believe our Metformin reformulation may show efficacy in treating a wide range of RD diseases that cause vision loss. We are focused on developing disease modifying therapeutics to meet the unmet needs of patients. The Company anticipates being prepared for human testing of this reformulation by third quarter of 2022.”
About Age-Related Macular Degeneration, Stargardt Disease, Retinitis Pigmentosa and Choroideremia
AMD is the leading cause of vision loss in people ages 60+. It destroys a patient’s sharp, central vision. Stargardt disease is a type of AMD that causes vision loss in children or young adults. Retinitis pigmentosa is a genetic disorder which leads to a gradual loss of sight, causing a deterioration of night vision and peripheral vision. Choroideremia is a hereditary retinal degeneration that causes a gradual loss of vision. It starts in early childhood with night blindness, then follows with peripheral vision loss and eventually progresses to the loss of central vision. Diabetic retinopathy is the leading cause of blindness in adults. Diabetes harms blood vessels inside the eye by weakening them so they leak fluid into the retina, which can damage areas of the retina, causing blurry, distorted vision.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |